-
Expert Rev Anticancer Ther · Dec 2007
ReviewCardiotoxicity associated with the use of trastuzumab in breast cancer patients.
- Patrick J Perik, Maarten Alexander de Korte, Dirk J van Veldhuisen, Jourik A Gietema, Dirk T Sleijfer, and Elisabeth G E de Vries.
- University Medical Center Groningen, Department of Medical Oncology & Cardiology, PO Box 30 001, 9700 RB Groningen, The Netherlands. p.j.perik@int.umcg.nl
- Expert Rev Anticancer Ther. 2007 Dec 1; 7 (12): 1763-71.
AbstractThe monoclonal antibody against HER2, trastuzumab (Herceptin), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and survival. The downside with the use of this agent, however, is its inherent cardiotoxicity, which is particularly common when anthracyclines are used concurrently. This review will focus on all aspects of the cardiac side-effects of trastuzumab, ranging from epidemiology and pathophysiology to cardiac monitoring, and treatment and prevention.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..